{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:07:36Z","timestamp":1780636056387,"version":"3.54.1"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;amp;D Transl Res &amp;amp; Clin Interv"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A dynamic simulation estimated wait times and treatment\u2010eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness\u2010to\u2010pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment\u2010eligible patients increased considerably with BBM\u2010based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased treatment\u2010eligible patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Replacing positron emission tomography (PET) or cerebrospinal fluid with BBM\u2010based diagnostics may increase treatment eligibility because of lower costs, driving higher demand for testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>A dynamic simulation models Alzheimer's diagnostic workflows in Japan.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Implementing BBM tests improves access to Alzheimer's diagnostics.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Study quantifies demand for diagnostic testing based on costs and accessibility.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Testing costs impact the number of treatment\u2010eligible Alzheimer's patients.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70157","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:30:17Z","timestamp":1759894217000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6916","authenticated-orcid":false,"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[{"name":"Department of Health Economics and Outcomes Research Graduate School of Pharmaceutical Sciences The University of Tokyo  Bunkyo\u2010ku Tokyo Japan"},{"name":"School of Data Science Yokohama City University School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurology Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ataka","sequence":"additional","affiliation":[{"name":"Department of Neurology Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temmei","family":"Ito","sequence":"additional","affiliation":[{"name":"Global Alzheimer Disease Eisai Co., Ltd  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Human Biology Integration Foundation Deep Human Biology Learning, Eisai Co., Ltd  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuru","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Human Biology Integration Foundation Deep Human Biology Learning, Eisai Co., Ltd  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayaka","family":"Tani","sequence":"additional","affiliation":[{"name":"Global Alzheimer Disease Eisai Co., Ltd  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Sakata","sequence":"additional","affiliation":[{"name":"Planning Department Medical Headquarters, Eisai Co., Ltd  Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Azuma","sequence":"additional","affiliation":[{"name":"Global Alzheimer Disease Eisai Co., Ltd  Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Chida","sequence":"additional","affiliation":[{"name":"Milliman Inc  Chiyoda\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Milliman Inc  Chiyoda\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Milliman Inc  Chiyoda\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Neurology Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_8_5_1","unstructured":"Ministry of Health Labour and Welfare.Optimal Use Guideline for lecanemab (genetical recombination). In Japanese.Ministry of Health Labour and Welfare. December 2023. Accessed April 7 2025. Available from:https:\/\/www.pmda.go.jp\/files\/000265885.pdf"},{"key":"e_1_2_8_6_1","unstructured":"Ministry of Health Labour and Welfare.Handling of guidelines for promoting optimal use. In Japanese.Ministry of Health Labour and Welfare. September 30 2022. Accessed April 7 2025. Available from:https:\/\/www.mhlw.go.jp\/web\/t_doc?dataId=00tc7062&dataType=1&pageNo=1"},{"key":"e_1_2_8_7_1","unstructured":"MattkeS Hl\u00e1vkaJP YoongJ WangM GotoR.Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer's treatment.CESR Reports;2019:2019\u2010101. Accessed April 7 2025. Available from:https:\/\/cesr.usc.edu\/sites\/default\/files\/Japan_Infrastructure_Report_Update_f2%5B1%5D.pdf"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/11786329241299312"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.05.017"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14150"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14184"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010024\u201000977\u20105"},{"key":"e_1_2_8_13_1","unstructured":"World Health Organization.Preferred product characteristics of blood\u2010based biomarker diagnostics for Alzheimer disease.World Health Organization;2024. Accessed April 7 2025. Available from:https:\/\/iris.who.int\/bitstream\/handle\/10665\/379286\/9789240099067\u2010eng.pdf?sequence=1"},{"key":"e_1_2_8_14_1","unstructured":"Guideline Development Committee.Appropriate Use Guideline for Cerebrospinal Fluid and Blood Biomarkers Related to Dementia. 3rd ed. Tokyo Japan: Japanese Society of Dementia Research Japanese Psychogeriatric Society Japanese Society of Neurology Japanese Society of Psychiatry and Neurology Japanese Society of Geriatrics Japanese Society of Neurological Therapeutics. In Japanese.Guideline Development Committee. March 31 2025. Accessed July 10 2025. Available from:https:\/\/www.jpn\u2010geriat\u2010soc.or.jp\/proposal\/pdf\/dementia03.pdf"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7248.1530"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082080899"},{"key":"e_1_2_8_18_1","volume-title":"Agent\u2010Based and Individual\u2010Based Modeling: a Practical Introduction","author":"Railsback SF","year":"2011"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd13.150561"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010publhealth\u2010040617\u2010014317"},{"key":"e_1_2_8_21_1","unstructured":"All Japan Hospital Association.Research Report on the Medical Care System for Dementia. Subsidized by the Health Promotion Program for the Elderly. In Japanese; title translated by the author.All Japan Hospital Association. March 2024. Accessed April 7 2025. Available from:https:\/\/www.ajha.or.jp\/voice\/pdf\/other\/240411_5.pdf"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13348"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12778"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.94"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12081"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2023.0309"},{"key":"e_1_2_8_27_1","unstructured":"National Institute for Health and Care Excellence.Draft guidance consultation. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease.National Institute for Health and Care Excellence. August 2024. Accessed April 7 2025. Available from:https:\/\/www.nice.org.uk\/guidance\/GID\u2010TA11220\/documents\/draft\u2010guidance"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010023\u201000473\u2010w"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/trc2.70157","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:54:48Z","timestamp":1780635288000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/trc2.70157"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70157","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70157"}}